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Treatment of Type 2 diabetes with glucagon-like peptide
(GLP)-1 receptor agonists leads to a modest increase in
fasting plasma pancreatic enzyme levels, i.e. lipase and
amylase [1,2]. The relevance of this observation is currently
unknown, although GLP-1 receptor agonists have been
linked to the development of pancreatitis [1]. The rate by
which these enzymes increase remains largely unstudied. To
date, the earliest observed enzyme increment is 4 weeks after
drug initiation, while elevated levels are sustained during
prolonged treatment [1,2]. In vitro, native GLP-1 increases
amylase secretion from isolated pancreatic acinar cells within
30 min [3], suggesting that the effect is immediate; however,
in a recent study by Sonne et al. [4], liquid meal-stimulated
endogenous GLP-1 (reaching two to three times fasting GLP-
1 levels) did not raise plasma lipase or amylase levels in
people with Type 2 diabetes within 4 h. Whether plasma
concentrations of therapeutic GLP-1 receptor agonist
increase pancreatic enzyme levels acutely in the clinical
setting remains unclear. In the present study, we measured
plasma lipase and amylase during i.v. administration of the
GLP-1 receptor agonist exenatide in people with Type 2
diabetes.
A detailed description of the design of this double-blind,
placebo-controlled trial has been reported previously [5].
Briefly, 57 people with Type 2 diabetes (mean  SD age
62.8  6.9 years, BMI 31.8  4.1 kg/m2, HbA1c 56  7
mmol/mol (7.3  0.6%), diabetes duration 7.8  4.9 years)
were randomized to exenatide (AstraZeneca, London, UK) or
placebo (isotonic saline). Exenatide was administered i.v.,
with a loading dose of 50 ng/min in 30 min, followed by
continuous infusion of 25 ng/min, which is known to achieve
steady-state plasma concentrations within the therapeutically
relevant range (130–150 pg/ml) [6]. Plasma lipase and
amylase were measured at baseline (~150 min before the
start of intervention), and repeatedly during intervention in
both the fasting state and after a high-fat mixed meal (905.7
kCal; 50 g fat, 36.8 g protein and 75 g carbohydrates), using
enzymatic colorimetric assays (Modular Analytics; Roche
Diagnostics GmbH, Mannheim, Germany). Statistical anal-
yses were performed using linear mixed models, which
inherently correct for the multiple time points tested.
Lipase and amylase levels were in the normal range at
baseline (mean  SEM lipase 44.6  3.3 U/l and amylase
50.7  2.4 U/l) and showed a similar initial decrease in both
intervention groups (between-group difference P > 0.05;
Fig. 1). Thereafter, plasma amylase levels showed an increase
during exenatide infusion, but not during placebo infusion.
After 280 min infusion, amylase was significantly higher with
exenatide compared with placebo (4.7  1.4 U/l; P = 0.001).
Amylase levels in individualparticipantsdidnotexceed3 9 the
upper limit of normal (maximum value was 110 U/l). Neither
exenatide nor placebo had an effect on plasma lipase levels.
We show for the first time that the GLP-1 receptor agonist
exenatide increases amylase levelswithin hours after treatment
initiation.The exactmechanismsbywhich exenatide increased
amylase cannot be concluded from the present study; however,
increased plasma pancreatic enzyme levels can be caused by
acinar secretion or leakage. Because in vitro data show that
GLP-1 inducesamylase secretion [3], it is likely that the increase
in amylase in the present study was caused by augmented
secretion.Also, incaseofacutecellulardamagewithexenatide-
infusion, a combined increase in amylase and lipase would be
expected [7], arguing against damage in the present study.
An initial decrease in both lipase and amylase levels was
observed. This could be explained by circadian rhythm,
because the baseline measurement and the first intervention
measurement were separated by 3 h. Intraday variability
has been shown in a canine study [8], and importantly, is
not affected by feeding status. The fact that meal ingestion,
and release of endogenous GLP-1, has no effect on
pancreatic plasma enzymes underlines our findings and
those of Sonne et al. [4]. However, the exenatide-induced
increase in amylase occurred after the test meal. Whether
this increase would have occurred without a test-meal
remains speculative, although levels tended to rise before
meal ingestion. Further studies are needed to determine the
clinical relevance of these modest pancreatic enzyme eleva-
tions, and whether these increases are modulated by food
intake.
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Salsalate treatment for prediabetes: a
therapeutic alternative?
Diabet. Med. 34, 592–594 (2017)
Recent studies [1,2] in insulin-resistant individuals without
diabetes have been unable to confirm previous findings [3]
that salsalate, a non-steroidal, anti-inflammatory salicylate
derivative can enhance insulin sensitivity; however, failure to
improve insulin sensitivity in overweight/obese, insulin-
resistant individuals without diabetes should not necessarily
lead to the conclusion that salsalate is without therapeutic
potential in this population. Indeed, an argument can be
made that administration of salsalate may be of unique
benefit to such individuals; that is, those who are overweight/
obese and insulin-resistant before gross decompensation of
glucose tolerance, but at increased risk of Type 2 diabetes
and cardiovascular disease.
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FIGURE 1 Pre- and postprandial effects of exenatide (circles, red solid line) and placebo (squares, black dashed line) on changes in plasma lipase and
amylase concentrations. The high-fat mixed meal was given 155 min after start of intervention. Asterisk indicates a statistically significant difference
(P < 0.05) between the treatment groups at that time point.
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